DYN

+ Watchlist + Portfolio

Dyne Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.78
52-Week Range: $11.65 – $27.31
Market Cap: $4.85B
P/E (TTM): —
EPS (TTM): -3.26
Dividend Yield: —

Advanced Metrics

Price/Book: 6.13
PEG Ratio: —
Return on Equity: -81.57%
Return on Assets: -38.96%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 12.02
Debt/Equity: 0.33
Total Debt: $233.35M
Free Cash Flow: $-317.14M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $4.34B

DYN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$142.76M	$210.76M	$281.41M	$398.33M
Selling, General & Admin	$28.20M	$31.40M	$62.48M	$69.85M
Operating Expenses	$170.96M	$242.16M	$343.89M	$468.18M
Operating Income	-$170.96M	-$242.16M	-$343.89M	-$468.18M
EBITDA	-$169.28M	-$234.26M	-$315.75M	-$437.97M
Pretax Income	-$168.10M	-$235.94M	-$317.42M	-$446.21M
Net Income	-$168.10M	-$235.94M	-$317.42M	-$446.21M
Diluted EPS	-3.23	-3.95	-3.37	-3.47
Diluted Shares	51.98M	59.68M	94.14M	128.44M

DYN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$172.15M	$121.63M	$435.45M	$893.37M
Current Assets	$265.59M	$129.38M	$659.28M	$1.13B
Total Assets	$306.32M	$165.08M	$691.23M	$1.19B
Current Liabilities	$28.09M	$51.09M	$42.26M	$50.63M
Long-Term Debt	—	—	—	$148.92M
Total Debt	$30.48M	$27.41M	$23.99M	$169.20M
Total Liabilities	$53.96M	$73.79M	$61.40M	$214.83M
Retained Earnings	-$396.57M	-$632.51M	-$949.93M	-$1.40B
Shareholders' Equity	$252.36M	$91.29M	$629.84M	$972.13M
Working Capital	$237.51M	$78.28M	$617.02M	$1.08B

DYN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$153.65M	-$188.16M	-$292.37M	-$403.21M
Capital Expenditure	-$3.07M	-$729.00K	-$2.38M	-$20.71M
Free Cash Flow	-$156.71M	-$188.89M	-$294.75M	-$423.92M
Depreciation & Amortisation	$1.68M	$1.67M	$1.67M	$2.05M
Stock-Based Compensation	$15.18M	$19.97M	$45.86M	$45.85M
Investing Cash Flow	$87.20M	$83.31M	-$204.08M	-$28.75M
Financing Cash Flow	$37.39M	$54.32M	$809.89M	$890.31M
Net Change in Cash	-$29.05M	-$50.52M	$313.45M	$458.35M

DYN Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$99.24M	$97.22M	$95.43M	$100.89M	$152.17M
Selling, General & Admin	$16.55M	$16.67M	$20.70M	$24.39M	$29.49M
Operating Expenses	$115.79M	$113.89M	$116.13M	$125.28M	$181.66M
Operating Income	-$115.79M	-$113.89M	-$116.13M	-$125.28M	-$181.66M
EBITDA	-$110.26M	-$104.61M	-$108.24M	-$116.10M	-$173.40M
Pretax Income	-$110.86M	-$108.04M	-$111.95M	-$120.85M	-$178.56M
Net Income	-$110.86M	-$108.04M	-$111.95M	-$120.85M	-$178.56M
Diluted EPS	-0.97	-0.76	-0.76	-0.73	-1.08
Diluted Shares	113.87M	141.81M	147.62M	165.04M	165.45M

DYN Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$485.04M	$573.61M	$893.37M	$753.10M	$676.11M
Current Assets	$697.95M	$806.26M	$1.13B	$1.02B	$937.89M
Total Assets	$728.99M	$867.06M	$1.19B	$1.08B	$994.01M
Current Liabilities	$41.47M	$59.85M	$50.63M	$51.25M	$78.03M
Long-Term Debt	$98.81M	$99.15M	$148.92M	$149.38M	$199.33M
Total Debt	$121.08M	$120.47M	$169.20M	$168.68M	$219.20M
Total Liabilities	$157.55M	$175.28M	$214.83M	$214.90M	$291.86M
Retained Earnings	-$1.18B	-$1.28B	-$1.40B	-$1.52B	-$1.70B
Shareholders' Equity	$571.45M	$691.78M	$972.13M	$865.05M	$702.15M
Working Capital	$656.48M	$746.41M	$1.08B	$969.78M	$859.86M

DYN Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$94.70M	-$90.78M	-$111.83M	-$144.92M	-$130.29M
Capital Expenditure	-$60.00K	-$19.18M	-$484.00K	-$221.00K	-$1.51M
Free Cash Flow	-$94.76M	-$109.96M	-$112.32M	-$145.14M	-$131.80M
Depreciation & Amortisation	$503.00K	$523.00K	$521.00K	$550.00K	$560.00K
Stock-Based Compensation	$10.52M	$11.08M	$11.23M	$13.08M	$14.98M
Investing Cash Flow	$6.77M	-$37.97M	$982.00K	-$2.39M	-$4.79M
Financing Cash Flow	$100.77M	$217.33M	$430.96M	$7.06M	$58.11M
Net Change in Cash	$12.85M	$88.58M	$320.12M	—	—

Market Snapshot

About

Dyne Therapeutics, Inc. is a clinical-stage muscle disease company focused on developing life-transforming therapies for people with genetically driven diseases. The company's proprietary FORCE platform enables the targeted delivery of therapeutic payloads to muscle tissue, potentially overcoming limitations of traditional approaches. Dyne is developing a pipeline of muscle-targeted therapeutics for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). The company's lead programs use antisense oligonucleotides and other therapeutic modalities precisely delivered to muscle cells. Dyne's approach aims to improve efficacy and reduce off-target effects compared to systemic delivery methods.